Calcitonin in nonthyroidal cancer

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Calcitonin (CT) is a hormone primarily associated with thyroid function.
• Its role as a tumor marker in various cancers has been investigated.
• Elevated CT levels can occur in non-neoplastic conditions, requiring careful interpretation.

Purpose of the Study:

• To evaluate the utility of plasma calcitonin (CT) as a tumor marker in common human cancers.
• To determine the prevalence of elevated CT in patients diagnosed with specific malignancies.
• To investigate potential confounding factors affecting CT levels.

Main Methods:

• A blind prospective study design was employed.
• Plasma CT levels were measured in patients with confirmed cancer diagnoses.
• CT immunoreactivity was assessed in tumor tissue extracts.
• Incubation studies were performed to rule out assay artifacts.

Main Results:

• Elevated plasma CT (>150 pg/ml) was observed in 38% of lung, 24% of colon, 38% of breast, 42% of pancreas, and 30% of gastric cancers.
• Fifty-eight percent of oat cell carcinomas exhibited elevated plasma CT.
• CT immunoreactivity was detected in 14% of tumor extracts, absent in normal non-thyroid tissues.
• Hypercalcemia was excluded as the cause of hypercalcitonemia.
• Assay integrity was confirmed, excluding label degradation artifacts.

Conclusions:

• Plasma calcitonin is elevated in a significant proportion of patients with common neoplasms.
• Calcitonin demonstrates utility as a potential tumor marker for various cancers.
• Further research is warranted to establish CT's definitive role in cancer diagnostics and monitoring.